Medpace Holdings, Inc. MEDP
We take great care to ensure that the data presented and summarized in this overview for Medpace Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MEDP
View all-
Black Rock Inc. New York, NY2.58MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.53MShares$1.21 Billion0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.19MShares$567 Million0.07% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT829KShares$396 Million1.43% of portfolio
-
State Street Corp Boston, MA783KShares$374 Million0.01% of portfolio
-
Mawer Investment Management Ltd. Calgary, A0696KShares$333 Million1.06% of portfolio
-
Geode Capital Management, LLC Boston, MA668KShares$319 Million0.02% of portfolio
-
Bessemer Group Inc Woodbridge, NJ582KShares$278 Million0.32% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny578KShares$276 Million0.28% of portfolio
-
Aqr Capital Management LLC Greenwich, CT540KShares$258 Million0.17% of portfolio
Latest Institutional Activity in MEDP
Top Purchases
Top Sells
About MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Insider Transactions at MEDP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 18
2025
|
Cornelius P. Mc Carthy Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+31.28%
|
$243,000
$54.99 P/Share
|
|
Jun 30
2025
|
Cornelius P. Mc Carthy Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50
+0.92%
|
-
|
|
Jun 30
2025
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
57
+6.84%
|
-
|
|
Jun 30
2025
|
Brian T Carley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62
+0.24%
|
-
|
|
Apr 24
2025
|
Fred B Davenport Jr Director |
SELL
Open market or private sale
|
Direct |
1,712
-36.35%
|
$515,312
$301.82 P/Share
|
|
Apr 24
2025
|
Fred B Davenport Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,710
+50.0%
|
$268,470
$57.17 P/Share
|
|
Mar 31
2025
|
Cornelius P. Mc Carthy Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50
+0.93%
|
-
|
|
Mar 31
2025
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
57
+7.35%
|
-
|
|
Mar 31
2025
|
Brian T Carley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
63
+0.24%
|
-
|
|
Mar 07
2025
|
August J. Troendle CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
356,446
+11.02%
|
$26,020,558
$73.09 P/Share
|
|
Feb 27
2025
|
Stephen P Ewald General Counsel & Corp. Secy. |
BUY
Open market or private purchase
|
Direct |
2
+0.02%
|
$652
$326.11 P/Share
|
|
Feb 24
2025
|
Brian T Carley Director |
SELL
Open market or private sale
|
Direct |
4,003
-13.33%
|
$1,381,035
$345.59 P/Share
|
|
Feb 24
2025
|
Brian T Carley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,127
+21.3%
|
$341,334
$42.62 P/Share
|
|
Dec 31
2024
|
Cornelius P. Mc Carthy Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62
+1.16%
|
-
|
|
Dec 31
2024
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
71
+9.69%
|
-
|
|
Dec 31
2024
|
Brian T Carley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
78
+0.35%
|
-
|
|
Dec 06
2024
|
Jesse J Geiger President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+29.12%
|
$480,000
$32.05 P/Share
|
|
Nov 19
2024
|
Susan E Burwig Exec. VP, Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+10.34%
|
$240,000
$32.05 P/Share
|
|
Sep 30
2024
|
Cornelius P. Mc Carthy Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62
+1.17%
|
-
|
|
Sep 30
2024
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
71
+10.73%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 455K shares |
|---|---|
| Open market or private purchase | 2 shares |
| Open market or private sale | 13.8K shares |
|---|